CA1024070A - Method of stabilizing a topical ophthalmic formulation - Google Patents

Method of stabilizing a topical ophthalmic formulation

Info

Publication number
CA1024070A
CA1024070A CA195,202A CA195202A CA1024070A CA 1024070 A CA1024070 A CA 1024070A CA 195202 A CA195202 A CA 195202A CA 1024070 A CA1024070 A CA 1024070A
Authority
CA
Canada
Prior art keywords
stabilizing
ophthalmic formulation
topical ophthalmic
topical
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA195,202A
Other languages
French (fr)
Other versions
CA195202S (en
Inventor
John R. Smythies
Vithal J. Rajadhyaksha
Frank J. Dea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US00341732A external-priority patent/US3824313A/en
Application filed by Allergan Pharmaceuticals Inc filed Critical Allergan Pharmaceuticals Inc
Application granted granted Critical
Publication of CA1024070A publication Critical patent/CA1024070A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
CA195,202A 1973-03-16 1974-03-18 Method of stabilizing a topical ophthalmic formulation Expired CA1024070A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US00341732A US3824313A (en) 1973-03-16 1973-03-16 Topical opthalmic composition and methods of use
US44568574A 1974-02-25 1974-02-25

Publications (1)

Publication Number Publication Date
CA1024070A true CA1024070A (en) 1978-01-10

Family

ID=26992634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA195,202A Expired CA1024070A (en) 1973-03-16 1974-03-18 Method of stabilizing a topical ophthalmic formulation

Country Status (7)

Country Link
JP (1) JPS5833202B2 (en)
CA (1) CA1024070A (en)
DE (1) DE2411019C2 (en)
DK (1) DK136884B (en)
ES (1) ES424362A1 (en)
FR (1) FR2221140B1 (en)
GB (1) GB1459264A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261181A (en) 2010-09-30 2013-08-21 索尔维公司 Derivative of epichlorohydrin of natural origin
US20210369686A1 (en) * 2018-10-06 2021-12-02 Biotheravision Llc Ophthalmic preparations of muscarinic agonist and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE300422B (en) * 1964-07-03 1968-04-29 Astra Ab

Also Published As

Publication number Publication date
DE2411019C2 (en) 1986-11-20
DE2411019A1 (en) 1974-09-26
DK136884B (en) 1977-12-12
JPS5833202B2 (en) 1983-07-18
FR2221140B1 (en) 1977-07-01
JPS5035320A (en) 1975-04-04
GB1459264A (en) 1976-12-22
ES424362A1 (en) 1976-10-16
FR2221140A1 (en) 1974-10-11
AU6679074A (en) 1975-09-18

Similar Documents

Publication Publication Date Title
CA1029303A (en) Method of contraception by the administration of stage-combination preparations
AU464655B2 (en) Cyclohexane derivatives
AU521892B2 (en) Sulphamoylbenzoic acid derivatives
CA969549A (en) 2-anilino-nicotinic acid derivatives
CA1028699A (en) Prostanoic acid derivatives
CA1034594A (en) Process for preparation of abietamide derivatives
CA1029302A (en) Method of contraception by the administration of stage-combination preparations
CA1024070A (en) Method of stabilizing a topical ophthalmic formulation
AU502146B2 (en) 11-epi-prostanoic acid derivatives
ZA741691B (en) Method of stabilizing a topical ophthalmic formulation
AU499409B2 (en) Cephalasporanic acid derivatives
CA1033741A (en) Derivatives of 4-hydroxy-5-azacoumarin
AU487102B2 (en) Method of stabilizing a topical ophthalmic formulation
CA1034577A (en) Thienopyridine-carboxylic acid derivatives
CA1014549A (en) Methyleneaminopenicillanic acid derivatives
AU8752175A (en) Isoclavulanic acid derivatives
CA1018546A (en) Method of preparing p-chlorophenylenedlamine
AU485928B2 (en) Method of cold-joining parts
AU486554B2 (en) 2-chloroethanephosphonic acid derivatives
AU482042B2 (en) Thienopyridine-carboxylic acid derivatives
AU467931B2 (en) Prostaglandin derivatives
AU482077B2 (en) Prostanoic acid derivatives
AU489508B2 (en) Penicillin derivatives
AU499171B2 (en) Clavulanic acid derivatives
AU488517B2 (en) Process for preparation of abietamide derivatives